Literature DB >> 14504696

The heterogeneity of bone disease in cirrhosis: a multivariate analysis.

Bronwyn A L Crawford1, C Kam, A J Donaghy, G W McCaughan.   

Abstract

This study aimed to assess the clinical, biochemical and hormonal factors contributing to low bone density in a large ambulatory group of patients with cirrhosis of diverse aetiology. Bone density of the lumbar spine, neck of femur, total hip, total body, as well as total body fat, was measured by dual X-ray (DEXA) absorptiometry in 81 men and 32 women (average age 50.3 years). Morning blood and urine samples were taken for hormonal and biochemical analysis. Viral hepatitis was the most common cause of cirrhosis (54%) and the severity of cirrhosis ranged from Child-Pugh A5-C14. Osteoporosis was most common in the lumbar spine but was present at any site in 31% of women and 22% of men, with osteopenia present in another 40% of both genders. Urinary deoxypyridinoline, a marker of bone resorption, was elevated in 56% of patients and was associated with increasing severity of cirrhosis and a higher prevalence of osteoporosis, particularly of the lumbar spine. Hip-bone density was primarily affected by low 25-hydroxyvitamin D levels and was associated with secondary hyperparathyroidism in one third of these patients. Additional important predictors for low bone density at all sites were age in women and testosterone in men. These findings indicate that, although the pathophysiology of osteoporosis in chronic liver disease is heterogeneous, high bone turnover may be the underlying pathophysiological mechanism in a significant subgroup of cirrhotic patients and may reflect metabolic effects of hypogonadism or secondary hyperparathyroidism on bone.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14504696     DOI: 10.1007/s00198-003-1495-z

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  39 in total

1.  Guidelines on the management of osteoporosis associated with chronic liver disease.

Authors:  Jane D Collier; M Ninkovic; J E Compston
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

2.  Vitamin D insufficiency among free-living healthy young adults.

Authors:  Vin Tangpricha; Elizabeth N Pearce; Tai C Chen; Michael F Holick
Journal:  Am J Med       Date:  2002-06-01       Impact factor: 4.965

3.  Osteoporosis and skeletal fractures in chronic liver disease.

Authors:  T Diamond; D Stiel; M Lunzer; M Wilkinson; J Roche; S Posen
Journal:  Gut       Date:  1990-01       Impact factor: 23.059

4.  Sex-hormone-binding globulin is an oestrogen amplifier.

Authors:  C W Burke; D C Anderson
Journal:  Nature       Date:  1972-11-03       Impact factor: 49.962

5.  Bone mass in women with primary biliary cirrhosis: the relation with histological stage and use of glucocorticoids.

Authors:  F N Van Berkum; R Beukers; J C Birkenhäger; P P Kooij; S W Schalm; H A Pols
Journal:  Gastroenterology       Date:  1990-10       Impact factor: 22.682

Review 6.  Bone disease in cholestatic liver disease.

Authors:  J E Hay
Journal:  Gastroenterology       Date:  1995-01       Impact factor: 22.682

7.  Bone loss and reduced osteoblast function in primary biliary cirrhosis.

Authors:  S F Hodgson; E R Dickson; H W Wahner; K A Johnson; K G Mann; B L Riggs
Journal:  Ann Intern Med       Date:  1985-12       Impact factor: 25.391

8.  Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment.

Authors:  J S Crippin; R A Jorgensen; E R Dickson; K D Lindor
Journal:  Am J Gastroenterol       Date:  1994-01       Impact factor: 10.864

9.  Bone disease in primary biliary cirrhosis: increased bone resorption and turnover in the absence of osteoporosis or osteomalacia.

Authors:  J A Cuthbert; C Y Pak; J E Zerwekh; K D Glass; B Combes
Journal:  Hepatology       Date:  1984 Jan-Feb       Impact factor: 17.425

10.  Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment.

Authors:  D S Matloff; M M Kaplan; R M Neer; M J Goldberg; W Bitman; H J Wolfe
Journal:  Gastroenterology       Date:  1982-07       Impact factor: 22.682

View more
  9 in total

1.  Total 25(OH) vitamin D, free 25(OH) vitamin D and markers of bone turnover in cirrhotics with and without synthetic dysfunction.

Authors:  Jennifer C Lai; Daniel D Bikle; Blanca Lizaola; Hilary Hayssen; Norah A Terrault; Janice B Schwartz
Journal:  Liver Int       Date:  2015-03-27       Impact factor: 5.828

2.  Vitamin D deficiency in cirrhosis relates to liver dysfunction rather than aetiology.

Authors:  Mikkel Malham; Søren Peter Jørgensen; Peter Ott; Jørgen Agnholt; Hendrik Vilstrup; Mette Borre; Jens F Dahlerup
Journal:  World J Gastroenterol       Date:  2011-02-21       Impact factor: 5.742

3.  Chronic non-cholestatic liver disease is not associated with an increased fracture rate in children.

Authors:  Jerzy Konstantynowicz; Dariusz M Lebensztejn; Elzbieta Skiba; Maria E Sobaniec-Lotowska; Pawel Abramowicz; Janina Piotrowska-Jastrzebska; Maciej Kaczmarski
Journal:  J Bone Miner Metab       Date:  2010-09-14       Impact factor: 2.626

4.  Vitamin D Metabolites Inhibit Hepatitis C Virus and Modulate Cellular Gene Expression.

Authors:  Julio A Gutierrez; Krysten A Jones; Roxana Flores; Akul Singhania; Christopher H Woelk; Robert T Schooley; David L Wyles
Journal:  J Virol Antivir Res       Date:  2014-10-06

Review 5.  Bone disorders in children and adolescents with chronic HCV infection.

Authors:  Anna Maccabruni; Marco Zaramella; Luisella Pedrotti; Stefano Lucanto; Silvana Quaglini; Redento Mora
Journal:  Clin Cases Miner Bone Metab       Date:  2014-05

6.  Impact of Vitamin D Status in Chronic Liver Disease.

Authors:  Mushtaq A Khan; Hilal A Dar; Muneer A Baba; Altaf H Shah; Bhagat Singh; Nadeem A Shiekh
Journal:  J Clin Exp Hepatol       Date:  2019-03-13

7.  Association Between 10-Year Fracture Probability and Nonalcoholic Fatty Liver Disease With or Without Sarcopenia in Korean Men: A Nationwide Population-Based Cross-Sectional Study.

Authors:  Hye Jun Lee; Duk Chul Lee; Choon Ok Kim
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-31       Impact factor: 5.555

Review 8.  The Role of Vitamin D and Vitamin D Binding Protein in Chronic Liver Diseases.

Authors:  Tudor Lucian Pop; Claudia Sîrbe; Gabriel Benţa; Alexandra Mititelu; Alina Grama
Journal:  Int J Mol Sci       Date:  2022-09-14       Impact factor: 6.208

9.  Pamidronate for the treatment of osteoporosis secondary to chronic cholestatic liver disease in Wistar rats.

Authors:  F A Pereira; R Mattar; I Facincani; H L A Defino; L N Z Ramalho; V Jorgetti; J B Volpon; F J A de Paula
Journal:  Braz J Med Biol Res       Date:  2012-09-11       Impact factor: 2.590

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.